Evrenzo (roxadustat)

Roxadustat induces erythropoiesis in erythroleukemia primarily by targeting HIF-2α and was partially GATA1-dependent. Besides upregulating erythropoietin, our study revealed the HIF-α/GATA1 axis as another critical regulatory mechanism for hypoxia-driven erythropoiesis.

In line, the HIF1α-stabilizing drug Roxadustat increased the number of CD14+ HLA-DR low cells...Our data dissect the intratumoral network of RCC and show that tumor-derived lactate promotes a pro-tumorigenic myeloid phenotype with low MHC-II but high immune-checkpoint, LOX-1 and S100A8/9 expression. Blocking MCT disrupts this interplay, offering a promising strategy to re-educate tumor-associated myeloid cells and enhance tumor immune surveillance.

P=N/A, N=200, Not yet recruiting, Zhongda Hospital

Consequently, Roxadustat poses a clinical dilemma: its efficacy in CIA offers a promising ESAs alternative, but its HIF-driven oncogenic potential necessitates long-term safety assessment in cancer patients. Future studies must prioritize longitudinal monitoring to define the benefit-risk profile.

P3, N=100, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Sep 2026 --> Oct 2027 | Trial primary completion date: Nov 2025 --> Oct 2027

Our findings support a potential causal relationship between the inhibition of EGLN1 and EGLN2 and the development of specific cancer types.

Panaxadiol suppresses cell proliferation, immunological evasion, and tumor formation in ESCC by inhibiting PD-L1 expression through the suppression of HIF-1α and STAT3.

P4, N=240, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting

P4, N=60, Not yet recruiting, Tianjin Medical University General Hospital

P4, N=60, Not yet recruiting, Department of Nephrology, Tianjin Medical University General Hospital; Department of Nephrology, Tianjin Medical University General Hospital

P=N/A, N=2104, Completed, Astellas Pharma Inc | Active, not recruiting --> Completed

Overall, Roxadustat triggered complex gene expression changes without promoting inflammation or oxidative stress in RPE cells. Despite these findings, ophthalmologic monitoring is advised during PHI treatment in CKD patients receiving HIF-PHIs.